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ELECTROPHYSIOLOGIC STUDIES
Dissociation of Termination and Prevention of Inducibility of
Sustained Ventricular Tachycardia With Infusion of Procainamide :
Evidence for Distinct Mechanisms
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Phidadrlp/io, Peaa .vy lraaia
To determine if ternlinatkrn of hemodynamleully Written,
sus-
tained
ventricular lachycardia during Intravenous L.faolon of
procalnmnlde predict: the success of procalnamide therapy in
preventing induction of tachycardla, IS patients wine inducible,
sustained ventricular tachycardia in the setting of chronic Bore .
nary artery dlstase were studied . Procahmmide was ;sins!+! .t a
rate of 50 mg/min during ventricular tahycadia until the ar-
rhytlrla terminated spontaneously or a total dose of 15 mr/kg
was administered . An Infusion (2 to 10 mg/min) was given after
the loading dose to maintain constant serum drug c
.mcearetans
after termination of the tachyeardia.
The infusion of procainarldc was well tolerated and resulted
In termination of ventricular tachycardia in 14 (9350) of 15
patients after administration of 100 to 1,080 rig (median dose
600 mgt. In alt patents, programmed veutrian :ar sdamWiun was
repeated Immediately after termination of rim arrhyttmia uat1
ventricular lue hy:ardia was reinitiated or until the stimulation
protocol was completed. Of the 14 patient ; whose ventricular
lachycardia terminated during the infusion of prucainamide, I
patient bad no Iducible sustained tachycardla with repeated
progronsmed stimalaton . In the remaining 13 patients, pro-
Procaitutmide may be administered intravenously in an at-
tempt to terminate ventricular tachycardia that is hemody-
namically tolerated
. However, there has been only limited
documentation of the
efficacy
of this practice (1 .2) . Success-
ful drug-induced termination may prompt empiric use of the
same drug for long-term oral antiarrhythmic therapy . It is
'mknown whether the mechanism responsible for tachycar
.
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grammed stimulation resulted In ladebon of sastaloed veMrica-
lar tachycardla of the same configuration In 7 paknts said of a
different a,nbgerMioa In 6 . In the farmer 7 patients, the serum
procainamlde concentration (7.7
t
4 vs . 7.43 3
.3 aglitter, p =
NS) and the observed drug eMeds on the taeltycardla cycle length
(449 a 78 is . 456 f 91 ms, p = NS) and QAS derides (184 ± 3$
vs. 185' 38 me, p = NS) were simlar a the times of termination
and reinitiatiam of ventrkuia mchycarnia.
la summary, infusion of proeshmaMe wins nine of the de
scribed dosing regimen terminated 93% of sustained, heao-
dynamically tolerated ventrkvlu (ac cadia episodes without
causing hypoteasion. The ahilily to terminate ventricular tadsy
cardia with an fusion of proalmadde did not re8ahty predict
subsequent success in preventing Inducible vemricalm tahyar-
din. Finally, the refadafon of ventricular tocisycorellis with an
identical configuration and daughter cycle length and at counting
serum procal amide eoncentradou mggens that, at least in
some
patients (7 of 13; 54%), the dectrophyebbgk meebmism of
drug-induced ventricular tahycu dia termimtbn is different
from that of arrhylhmhr prevention,
(I Am Call Cordial 1992:19:111-7)
dia termination during procainamide infusion is related to the
mechanism of drug efficacy in
preventing recurrent sponta-
neous or induced episodes of ventricular tachycardia . If the
mechanisms are identical, then
if ventricular tachycardia
terminates during proeainamide infusion, the tachycardia
should not he inducible, or should only be nonsustained, as
long as a constant serum procairamide concentration is
maintained .
The purpose of this study was to define the incidence of
ventricular tachycardia termination with procainamidc infu-
sion and to determine if termination predicts subsequent
success in preventing ventricular tachycardia induction dur-
ing maintenance of a constant drug concentration . To ensure
that the drug concentration and the electrophysiologic ef-
fects of procainamide were constant at the time of termina-
tion and reinitiation of ventricular tachycardia, we also
compared the cycle length (an index of conduction velocity
in the presumed arrhythmia circuit) and the QRS duration
(an index of conduction velocity in the remaining myocar-
dium) during ventricular tachycardia at both time points
.
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Tibia 1 . Clinical Chalaceerieiics of 15 Pahcals
'Surface QR9 can'guralion during venuicul-h"ynedia ou the elec .
rrocsediogram (ECO), The En too Idlers irtdpte lie pullern at tundIc
blanch block (LB = lea bundle, RB = right burble); the second two letters
indicate the axis in the frontal plane IL = left . R = right . I = interior. S =
superior) . AM[ = anterior myocardial inlarctim ; EF = tell vemricular
ejection traction ; IMI = inferior myoardel i11lareton: M = male: NA = not
available .
Methods
Study patients (Table 1) . Fifteen patients with coronary
artery disease and prior myocardial infarction (mean ejection
fraclian 33%) were studied . Twelve patients had recurrent
Table 2 . Ventricular Tachyeardia Characteristics and Response to Prdeoimmide in 15 Patients
hemodynandcally mlerated vemricular tachycardia . one 1,4
syncope and two had cardiac arrest with inducible ve=ristr
ular tachycardia. All patients had reproducibly inducible
sustained ventricular tachycardia with prone smmed stimula-
tion at baseline study (Table 2), Our stimulation protocol has
been previously described in detail (31, Briefly, single . dou-
ble and triple ventricular ea(rastimuli were introduced dur-
ing paced cycle lengths of 1110 and 400 ms from the right
ventricular apex and outflow tract . Deeremental ventricular
pacing at cycle lengths sf 350 to 250 ms was performed from
the right ventricular apex . Left ventricular stimulation was
performed from at least one site if ventricular tachycardia
was not induced with right ventricular stimulation . Synchro-
nous square wave pulses were delivered at twice the dia-
stolic threshold with a I-ms pulse width. A custom-designed
stimulator (Bloom Associates) was used in all studies . At the
lime of baseline ventricular tachycardia induction . none of
the patients were receiving antiarrhythmic agents. Studies
were performed after written . informed consent was ob-
tained from each patient . The study protocol was approved
by
the Institutional Review Board of the University of
Pennsylvania .
Bustling ventricular lachyerdin characteristics (Table
2).
Fifteen episodes of sustained, hemodynamicatly well toler-
ated ventricular tachycardia
. were studied . None of the
episodes were associated with symptoms of angina, dyspnea
or light-headednesst the systolic
pressure during tachycardia
was ° 100mm Hg in all patients
. The mean tachycardia cycle
length was 369 ! 39 ms (range 310 to 450). Programmed
"Ventricular tachycardiawmIeinitiateds5minafteritslemiato
.
;
. .. dog levt6 .- be (he same at both times . CL-1 ty,k Itognpaglhjuo
berore pracainamide irdusloa. CIA = eyd, length just before laehyarda termination or at cnmptetion of the proairamib infusion
. I
D) = a different
confguration of lachyeada I- that of the terminated eadyccrdh : Doe = -at
of peoc amide infused a1 the time of rachywrdn termi sLinn or at
completion of the tolxl inrasiom ES = e :amsunuli: NA = r wavuhhle : NI = eoeitrducible
:ll4S + D) = rorrusloitled Iacttpeardia of the sanecouaguradoo and
sustained Io .:hyaldie ofa diderenl configuration
; RP = rapid ventncutorpoiog ; 251 = the same techyardia confguralton as Ihal of Ibe tennioated tachycardia .
Serum Level I and Semm Loud 2 iadioole cuncenrt iliom of p-einamik measured . respectively . at the rime of arrhythmia eermiretion or wmpletioe of the
loading dose (level 1) or al the tine of reirdtialiml of the tachycardia or completion of the stimulation prnlaui ifrto arrhylhmias were induced Ikvel 21'
. T-
= termimtion
; VT = vmtriculsr richycaldia.
Episode
No .
Before Pwwioc nie Rocuina,ride Ind.- trter Itne0humtde
Mode or
trducrion
VT CL-1
toll
VC CL-2
tool
Do.
1 .0
Serum Levd I
T-
17
Ri .ilio .d
Sc. so LevnI2
Crash .;
Mode of
trill
I
RP
380 400 Le 11 .1 Yce Y" (s) 11.1
sm.-
I 2
Double ES 440
5m 620 1 .1 Yes Yes (57 5.g Double PS
3 Double ES 395 430
IUD 2 .9 Yes Yes (S) 3A Duu*ES
4 SingkES 370 450 471 62
Yes Yes is) 8.2 • SednES
5 [1-16L ES 350 450 1 .100 10.3 No
Tel 101 8.5 RP
6 Triple ES 320 350 200 4.8 1'u Yes 19) 4.) 0
Triple ES
7 VT,tk E5 380 430 448 7,8 Yes Yeslbl 5 .8
Dorrk Es
B Sink E5 360 590 900 12.7 Yes Y., 15) 12 Sire ES
9 steroarmoas 450 51e 7310 9 Yes YeslOl 9' Single E4
10 Double ES 310 380 5m 9.5 Yes YeoIra 46 Triple ES
I I
Sleek ES 370 460 9m 5 Yes Yen (N5 t D) 4 .5 Tnpk ES
12 Sr-. 365 490 510 NA
Yes Y. (M NA Single ES
13 single ES 351 .765 710 5.5 Yes Ycn(SI 5 .1 Singe 1S
14 Unable Es 390 510
1 .(59 to Yes No BY N1
15 Double ES
340 400 500 13.1 Yes Ye61DY 12 .1' Spontaneous
Patient
Ne.
Age(Yrf
Gender
VT QRS
Cennguratiou' Infild Silt
EF
ell
1 MOM RBRS IMI 29
2 MOM LBLI 141 34
3 771M RBLS
AM[
RA
5714 LORI IMI 35
5 5114
ROES IMI 23
6 5514 Re RI AM, 34
7 594 RBRI IMI 37
0 6114 LOBS AMI 21
e 7&51 LBLS AMPIMI 26
10 5214 RBRI AMP1MI 19
II 671M LBLS 141
t1
12 721M LB L5 IMI 47
13 70im RBRI IMI 41
34 71M RERs AMIrIMI Is
15
QM LBLS AM[ NA
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stimulation !luring ventricular tachycardia was rotrtircly
performed for analysis of the response to resetting and
entrainmem and to facilitate tachycardia mapping. As a
result or the extrastimuii delivered during ventricular tachy-
cardia. episodes were occasionally terminated and subse-
quently reinduced . Over periods ranging in duration from 5
to 60 min during which programmed stimulation and map .
ping were not performed, no episode of ventricular tachy-
ardia was observed to terminate spontaneously .
Administration of procainamlde and study
protocol
Be-
fore administration of procainamide . the index episode of
ventricular mehycardia was demonstrated to have a stable
cycle length and tachycardia did not terminate spontane-
ously during an observation period of a5 min
. Procainamide
was then infused intravenously at a rate of 50 mg/min until
the tachycardia was terminated or until a total dose of
15 mgtkg body weight was administered
. In an attempt to
maintain constant serum concentrations . the procainamide
inhtsion was continued at a rare of 0 .11 µgtkg per min .
multiplied by the proportion of the total loading dose re-
quired €m arrhythmia termination (2 to 10 mgimml . We have
previously documented (4) that a similar dosing regimen
results in stable proeainanude concentrations . After ventric-
ular tachycardia was terminated by procaisamide infusion or
by pacing intervention (after infusion of the total dose of the
drug without effect), programmed stimulation was repeated
until ventricular tachycardia was initiated or until the stim-
ulation protocol, including up to 3 extrastimuli introduced
from at least two right ventricular sites, was completed . A
left ventricular sae was also used for stimulation if it was
required for initiation of the arrhythmia at baseman study .
Serum samples
to determine procwnamide and N-acetyl
procainamide concentrations were obtained at the
time of
termination or
the completion of the loading dose (level I I
and also when ventricular tachycardia was reinitiated or at
the end of the stimulation protocol if no arrhythmias were
induced (level 2). In five patients, a second serum sample fur
procainamide concentration was not obtained because rein-
itiation of ventricular rachycardia occurred within 5 min
after termination. In one patient both levels were unavailable
because of an error made in the laboratory . Ventricular
tachycardia that was reinitiated was allowed to persist for
m2 min before an attempt was made to terminate the
arrhythmia by pacing.
Data analysis . Three to five surface electrocardiograpbic
(ECG) leads (1, 11, and V, plus III and VA
) and one to four
intracardiac bipolar electrogmms were recorded continu-
ously on ink jet paper at 25 to 100 mats (Siemens Elema
Miogograph) and stored on magnetic tape, A 12-lead ECG
was recorded during all ventricular tachycardia episodes to
assist in confirmation of the diagnosis and to delineate the
QRS configuration of ventricular tachycardia . The QRS
configuration, taehycardia cycle length and QRS duration
were assessed before drug administration, immediately be-
lore termination of the tachycardia and at the time of
reiniliation with use of programmed stimulation. Measure-
113
mrntr were made with manual calipers. Termination se-
quences were reviewed to ensure that they did not result
from circumstances that were unlikely to be due to drug
effect, such as supraventrieular capture beats . Cycle length
variability was assessed by determining the standard devia-
tion of the mean cycle length (5I over three periods ; I) during
stable tachycardia (>30 s after initiation), 2) from 31 to 21
beats before termination . and 3) from 11 beats to 1 beat
before termination
. A significant increase in cycle length
variability in the period before ventricular tachycardia ter-
mination (from beats Is to beat I before termination) was
defined as an increase
In the standard deviation of the mean
cycle length to a2 times that of the baseline period (a I0-beat
period >30 s after initiation)
. Cycle length variability was
measured with use of an X-Y digitizing board (GICO)
interfaced to a computer (Newton-Packard 9836) .
Statistical analysis. Results ore reported as mean values
S0
. Paired observations were compared with a Student's
1 test
. This test was also used to compare differences in
baseline ventricular tachycardia characteristics in groups
differentiated by the success or failure of drug infusion in
terminating ventricular tachycardia and by the ability of
repeal programmed stimulation to reinitiate sustained ven-
tricular tachycardia of the same configuration as that in-
duced in the baseline state
. A p value < 0 .05 was considered
significant.
Results
Termination
or ventricular mebytardla with Infusion of
prveainnnide . Infusion of procainamide terminated ve^trio-
ulcer tachyeardia in 14 (93%) of 15 patients . Drug infusions
during sustained ventricular taetaycardia were well tolerated .
Systol is blood pressure remained >80 mm Hg in all patients,
and none had symptoms related to hypotension . The total
dose of procalnamide infused at the time of tachycardia
termination ranged from 100 to 1,080 mg (median 600), and
the scrum concentration ranged from 2 .9 to 13 .1 mg4iter
(median 5.9) . None of the episodes of tachyeardia termi-
nated as the result of supraventricular capture beats, in only
three episodes was there a change in arrhythmia configura-
tion for I to 4 buts immediately before termination . In 58%
of episodes, a significant increase in the variability of the
cycle length (doe standard deviation of the mean cycle length
increased .v2 times that a baseline study) was seen in heats
i I m I before drug-induced termination of the arrhythmia.
Reinitiation of ventricular taebynrdla by repent pro
gummed stimntatko (Trhke 2) . Only one patient had no
inducible sustained arrhythnuas after procainamide-induced
termination of tachycardia Sustained vcntriculartaehycar-
dia was reinitiated in 13 of the 14 patients whose tachycardia
had been terminated in response to procainamide infusion .
All episodes of ventricular tachycardia that were reinitiated
were well tolerated and patients were treated with pacing or
infusion of additional proeainamide after a wait of z2 min to
ensure that the tachycardia would not terminate spontane-
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ously
. Serum procainamide concentrations at the time of
tachycardia termination were similar to those obtained at
the time of its reinitiation (8 .3 ± 3 .2 vs . 7 .4 ± 3 .3 mglliter.
respectively, p = NS) .
hrduction of ventricular tachycardia with the same tnnfig .
uratlon
. In seven patients, repeat programmed stimulation
resulted in initiation of a sustained ventricular tachycardia
whose QRS configuration was identical to that of the tachy-
cardia that terminated with prtcainamide infusion . An ex-
ample of such an episode is seen in Figure 1
. The ability to
reinitiate ventricular tachycardia was not due to changes in
serum drug level (level 1, 7 .7
Y
4 mgJliter vs . level 2, 7 .4 ±
3 .3 mgfliter
. p = NS) (Fig. 2) . There were no dilcrcnces in
the effect of procainamide on conduction as indexed by the
Iaehycardiacyele length (449 a 78 vs . 450 ± 81 ms, p = NS)
or Qk5 duration (184 2 38 vs, 185 n 38 ms, p = NS)
immediately, before termination of the tachycardia and at the
time of reinitiation (Fig
. 2)
.
Induction of renrricuiar tarhyeardfo with a different
svnfigtrmfon . In 6 of the 13 patients in whom sustained
ventricular tachycardia was induced after successful pro .
sminamid,,e.-.,ien.d, uced nrrhythmin termination, only tachycardia
with a configuration different from that of the hatminatad
mtfiythmia could be induced . In two of these cases the
configuration of the terminated arrhythmia could not be
induced despite completion of the pacing protocol, and in
one patient
. the previous configuration could be initiated but
was always nonsustained (<30 s ; Fig . 3) . In the three
JACC V.I . 19, No. I
1muery 1992 :111-7
Fignre L Analog recording demen-
strating termination and spontaneous
reinitiation of ventricular tachycardia .
Three surface etectrocardiographic
ISCGI lead . (t . II and V,) and ietrs-
cardiac recordings from the right ven-
tricular apes (RVA) and left ventricle
(LV) awl eme
In. (TI are drown.
Pond A shows a right buome right
superior IRBIeS) axis tachycardia !hat
was induced at baseline study, The
cycle length (CL) was 310 ms and the
QRS duration during ventricular laehy-
cardia (QRS) was 200 ms. In prod h,
the tachyeardia renniomes daring pr
.
cainamide infusion. The se mm drug
concentration at termination was
13 .1 mglliter, the ventricular tachycar-
dia cycle length was 400 ms and QRS
duration was 250 no, Without a signif-
icant change in serum concemeatien or
drug effect Ian indexed by ventricular
lachycatdia cycle length and QRS dw
ration),
the same right bundle right
superior axis ventricular tabycardia
begins spontaneously, as shown in
pod C. Procainamide concentration
levels are given in mgliter .
remaining patients, the stimulation protocol was not com-
pleted because of patient fatigue after ventricular tachycar-
dia of a different configuration from that of the baseline state
was induced.
Use of baseline charaderbtks to predict aatoole. To
determine variables that might identify patients who would
have no inducible arrhythmia after ventricular lachycardia
was terminated during procainamide infusion, we compared
the seven patients in whom ventricular tachycardia with the
same configuration as that prior to termination was reinifi-
ated after pacainamide infusion with the patients in whom
ventricular tachycardia was no0lttducible, or in whom only
nonsastained ventricular tachycardia of the
same configura-
tion or sustained ventricular tachycardia of a different con-
figuration was induced despite completion of the stimulation
protocol- Because different polo] doses of procanumade were
administered in each patient, only baseline measurements
were compared. At baseline study, the ventricular tachycar-
dia cycle length (374 a 38 vs. 358 *- 34 ms, p = N5) and the
QRS duration (174 a 45 vs . 151 a 13 ms, p m NS) were
similar for the two groups .
Discussion
Efficacy of intravenous procninamide in termination
III
ventricular tachycardia. This study demonstrates that intra-
venous procainamide is highly effective in terminating well
JACC Vnl . 19, Nc
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A.
esa
drug-induced hypotension (systolic pressure <80 mm Hg or
symptoms of decreased cerebral perfusion) were noted. Our
findings are consistent wish those of Wellens et at- (t), who
reported termination of 10 of 12 sustained ventricular tachy-
cardia episodes during or within 2 min of intraatrial admin-
istration of a 10-mg/kg dose of procainamide ever 5 min
without any observed adverse effects, Serum procainamide
concentrations were not reported in their study . Preliminary
data from florgcls el al . (2) also demonstrated that intrave-
nously administered procainamide is effective and superior
to intravenously administered lidocaine in terminating sus-
tained ventricular tachycardia . The efficacy and safety dem-
onstrated in these studies and in the present study occurred
with infusion rates of procainamide greater than those com-
monly recommended (6) . These findings support the use of
intravenous procainamide administered at higher doses and
' rates of administration in the management of patients with
sustained, hemodynamically tolerated ventricular tachycar.
dia .
Reinitiatiion of ventricular tachycardia after drug-induced
termination
. in the majority of patients who had successful
termination of ventricular tachycardia, the tachycardia was
inducible during repeat programmed stimulation even
though serum drug concentrations immediately before tee.
mination and on reinitiation were constant . A disparity
between drug effects on tachycardia termination and reiniti-
alion bee been previously reported (7,8) in the treatment of
reentrant supraventricular tachycardiar with flecainide,
These dam argue against the practice of initiating empiric
antiarrhythmic drug therapy on the basis of successful
drug-induced termination of ventricular tachycardia without
electrphysiolegie investigation. However. our results apply
to the ability to induce ventricular tachycardia and not to its
spontaneous development .
Not only was tachycardia reinitiated in 93% of patients,
but in seven patients sustained ventricular tachycardia with
the same configuration, cycle length and QRS duration was
reinduced after termination of the arrhythmia during pro .
cainamide infusion. This finding suggests that separate
mechanisms of drug action are operative in tachycardia
termination and prevention of arrhythmia induction, at least
in this subset of patients . In these patients, our results
suggest that termination of ventricular tachycardia did not
occur because era critical, fixed increase in refractoriness or
permanent induction of bidirectional block in a presumed
reentrant circuit, either of which should have precluded
reinitiation of ventricular tachycardia . Our findings do not
exclude the possibility that time-dependent effects on con
.
duraion and refractoriness are important
; that is, all episodes
of ventricular tachycardia that were reinduced may have
tolerated, sustained ventricular tachycardia
. Fourteen of 15 terminated spontaneously if given enough time . However,
ventricular tachycardia episodes that had not terminated maximal Me-dependent effects of procainamide en Y
m„
spontaneously terminated during procainamide infusion at a develop within a very short half-time
(9), and episodes of
rate el SO mghrin . Funherrnure . this dosing regimen ap ventricular tachycardia that were reinitia€ed were observed
peared to be well tolerated in all patients . No episodes of for several minutes without intervent[ou .
ass -
2n0
so
tarmleatlen wlnluntlon
terndnetlon ,Nnltl∎ROn
t •
terndndlon reirmatlon
piper 2. Characteristics of ventricular tachycardia (VT) cycle
length (Ay, QRS duration (B) and serum procainamide concentration
(C). The same configuration of ventricular tachycardia was reiniti-
ated after procinamide-induced ventricular tachycardia termination
in the seven cases shown
. The changes in drug erect on indents of
conduction (ventricular tachycardia cycle length [Ai and QRS
duration [B]) and in serum drug concentrations
(C) are not of
sufficient magnitude
to otptaie the dissociation between successful
Mrg.indttced termmatioti of ventricular tachycardia and prevention
of ildacible arrhythmias (see text for further discussion) .
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PIgureS . Reinitiatiunafvmmriculartachy .
cardia after procainandde.ithiueed termi .
nation or the arrhythmia . The viulug r-
cordiuas are similar to those in Figure 1 .
except that (lit inlracardiac recordings are
firm the right ventricular apex (RVA I and
outflow tract IRVOT) . Pond A, A lea
bundle left superior ILBLSI axis ventricu .
lar lachycardia is shown at the time of
-
y„
^sdudngprncunamideinfusion
.
The serum praeainamide eaatenvation
was 5 mgfiter . trued R, At a similar pro.
cahwnide concentration . the left bundle
tell superior venuicular tachycardia was
repr u y induced but wasatways non-
sustained . PanetC.A di[ereul ventricular
tachycardin
configuration
that was ins-
taiaed was reproducibly imtuvxd with dou-
blt
ventricular
exlrastinurli from the rght
ventricular apex . Utherabbrevialiors as in
Figure I .
ib
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PROCAMA IDE 0
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Mechanism of proralnmide's antiarrhylhmic effects. Al-
though the effects of antiarehylhmic agents on isolated
muscle strips and individual myocytes are fairly well under-
stood
(9,10), the mechanism of their antiarrhythmic action in
the intact organism has not been completely characterized
.
Procainamide is known to increase refractoriness, slow
conduction and increase tachycardia cycle length
(11) . How-
ever, the action of procainamide that leads to termination of
ventricular tachycardia or prevention of arrhythmia recur-
rence is unknown, and may be unrelated to effects on
conduction and refraclariness observed in must patients .
Our previous observations an the increase in cycle length
variability that accompanies spontaneous ventricular rachy-
cardia termination (5) and those of Frame et al . (12) in an in
vitro model
of reentry Support the hypothesis that sponta-
neous termination of ventricular tachycardia frequently oc-
curs as the result of somewhat unpredictable changes in
refractoriness and, in rum, conduction, rather
than by fixed
effects on conduction or refractoriness within the circuit . If
this is true, it may be that antiarrhylhmic drugs merely
potentiate oscillations in refractoriness and local diastolic
intervals within the presumed reentrant circuit such that the
particular circumstances that lead to arrltythnt v termination
are more likely to occur
. Obviously, these same electrophys-
iologic conditions may not pert, allowing for me immcdi-
ate rcinduction of ventricular tachycardia . Drug effects on
hernodynantic status and changes in autonomic nervous
system tow may also play a role by providing transient
influences important in arrhythmia termination that may not
JACC Vo1 . 19. Nw 1
be
duplicated at the time of reinitiation of ventricular tachy-
cardia.
Two patients had Itonsustained ventricula : tachycardia
initiated that had the same QRS configuration as that of the
tachycardia that was terminated with procainamide infusion
.
This
finding suggests that procainamide may exert a fixed
effect an the tachycardia circuit in some patients . The ability
to induce only nonsestained ventricular tachycardia may
indicate that the same influences that resulted in the initial
termination of the ventricular tachycardia occur every time
the arrhythmia is initiated . In the patients who had
only
sustained tachycardia with a different QRS configuration
after procainamide infusion, it is possible that the presumed
reentrant circuit responsible for the original mchycardia
configuration was functionally obliterated by the thug infu-
sion ; this is mom likely to be true in the two patients in
whom the same tachycardia was not induced despite com-
pletion of the stimulation protocol
. Alternatively, the inabil.
ity to induce the original ventricular tachycardia configua-
lion after drug treatment may only reflect changes in the
conduction properties of the intervening tissue between the
point of stimulation and the ventricular tachycardia site of
origin, such that the circuit is not entered with a sufficient
degree of prematurity (13) . We found no characteristic of
ventricular tachycardia episodes at haseline study that iden-
tified patients who would not have inducible ventricular
lachycardia of the same configuration after procaiesnmide-
induced arrhythmia termination,
A)
PROCAINAMIDE 5
.0 LBLS CL 460
ORS 190
e
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r
B) PROCAINAMIDE 4.5 ! BLS
CL 460 OAS 100
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Limitations. This study included only patients with
chronic coronary artery disease and ventricular tachycardia
that was well tolerated hemodynamically and unassociated
with symptoms of angina or dyspnea. Our findings may not
be applicable to ventricular mchycardia episodes with dif-
ferent clinical presentatiunr, however, it is unlikely that
other clinical situations would be considered appropriate for
the intravenous infusion of procaina~mide .
An
additional
[imitation is the inability to determine whether termination of
ventricular tachycardia during procainamidc infusion was
the result of a definite drug effect or of a spontaneous,
unrelated event. We believe that it was related to the drug
Infusion because we documented that each tachycardia did
not terminate spontaneously on any occasion, Indaced epi-
sodes of tachycardia were observed fcr 5 to 60 min without
intervention (see Methods) and the final induced episode that
was treated with proceinumide infusion wrs otserved for
?5 min before the infusion was initiated . Thus, although it is
conceivable that some of the air hythnlia Jcrminatiops appar-
ently caused by procainamide were unrelated to its etectro-
physiologic effects, our methodology and strict entrance
criteria make this possibility extremely unlikely .
Conclusions. Procainamide appears to he safe and highly
effective in terminating well tolerated sustained ventricular
tachycardia when infused at a rate of 50 mg/min. which is
higher than the currently recommended rate of administra-
tion
. However, sustained ventricular tachycardia was imme-
diately reinitiated in most patients in whom it was terminated
during procainamide infusion . and in more than half
of these
patients, ventricular tachycardia of the sameQRS configura-
tion was reinitiafed . The fact that most patients had ventric-
ular tachycardia reinduced despite maintaining relatively
constant serum procainamide levels suggests that, in many
patients, the mechanisms responsible for drug-induced ter-
mination of ventricular tachycardia and prevention
of
induc-
ible arrhythmias arc dierent .
i L7
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